case_images: PMC11782023_01
case_images: Timeline of patient treatment and efficacy assessment. The "Treatments" section shows the time course of the treatment regimens, including immunochemistry, immune maintenance, and attempt of DS-8201. The "CEA curve" section illustrates the dynamic changes in tumor marker levels over time. The "Images" section displays chest and abdominal CT scans and brain MRI images at different stages of disease development, with efficacy assessments based on RECIST criteria. Red arrows indicate tumor lesions. CEA, carcinoembryonic antigen; CT, computed tomography; MRI, magnetic resonance imaging; PD, progression disease; PET, positron emission tomography; PR, partial response; q3w, quaque 3 weeks; RECIST, response evaluation criteria in solid tumors; SD, stable disease.
case_images: fonc-14-1469438-g001.jpg
case_images: PMC11782023_01_fonc-14-1469438-g001.jpg
case_images: f1
case_images: SCC (35.0ng/mL), and PROGRP (69.90 pg/mL), while CEA (2.71ng/mL) level was within normal limits ( Figure 1 ). Subsequent needle biopsy of the right lung mass confirmed the diagnosis of invasive lung adenocarcinoma with low programmed cell death ligand 1 (PD-L1) expression (tumor proportion score (TPS) < 1%) and harboring mutations in ERBB2 exon20 p.Y772_A775 dup with frequency of 79.98% and Figure 1 ). The patient was staged as cT2aN3M1b and IVA. Four cycles of immunochemistry treatments with sintilimab in combination with pemetrexed and cisplatin were initiated on June 7, with a 10% reduction in chemotherapy dose due to the patient's poor pulmonary function and Cancer and Aging Research Group (CARG) score of 4.
case_images: PMC11782023_02
case_images: PMC11782023_03